A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan

@article{Kohno2004AMO,
  title={A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan},
  author={Shigeru Kohno and Toru Masaoka and Hideyo Yamaguchi and Takeshi Mori and Akio Urabe and Akira Ito and Yoshihito Niki and Hideo Ikemoto},
  journal={Scandinavian Journal of Infectious Diseases},
  year={2004},
  volume={36},
  pages={372 - 379}
}
The efficacy and safety of micafungin (FK463), which is a new lipopeptide antifungal agent of the echinocandin class and is active against both Aspergillus and Candida species, were investigated in patients with deep-seated mycosis in this study. 70 patients were treated with micafungin 12.5–150 mg/d intravenously for up to 56 d. The overall clinical response rates were 60% (6/10) in invasive pulmonary aspergillosis, 67% (6/9) in chronic necrotizing pulmonary aspergillosis, 55% (12/22) in… 
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
TLDR
Micafungin shows promise as a safe and effective agent for the treatment of newly diagnosed and refractory cases of candidemia and large-scale, randomized, controlled trials are warranted.
[Antifungal activity and clinical efficacy of micafungin (funguard)].
  • F. Ikeda
  • Biology, Medicine
    Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology
  • 2005
TLDR
The results from this study indicated that micafungin was effective in aspergillosis and candidiasis, with no tolerability problems.
Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders
TLDR
The usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs is indicated, despite broad-spectrum antibacterial treatment over 2 days.
Micafungin: a therapeutic review
TLDR
Micafungin is expected to increase the efficacy rate of treatment in patients with severe aspergillosis or candidiasis when used in combination with amphotericin B or mold azoles.
Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report
TLDR
The post-marketing findings show that micafungin is effective against deep mycosis caused by Candida or Aspergillus in patients across a range of backgrounds.
Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study.
TLDR
MCFG has favorable efficacy and safety profiles in Japanese CPA patients with various backgrounds, comparable to the results obtained in clinical trials for marketing approval conducted in Japan.
Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study
TLDR
The effectiveness and safety of micafungin as an empirical therapy for suspected IFIs, including FN, and the usefulness of monitoring both BG and GM to detect breakthrough IFIs are indicated.
Clinical efficacy of micafungin for chronic pulmonary aspergillosis.
TLDR
A retrospective study is performed using data from nine patients with chronic invasive forms of pulmonary aspergillosis who were treated with Micafungin alone or together with other antifungal drugs between April 2003 and March 2004 to suggest that MCFG may be an effective and safe antIFungal drug for the treatment of chronic invasive Forms of pulmonary Aspergillus infections.
Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm
TLDR
MCFG had high clinical efficacy and safety in the treatment of deep-seated fungal infections in surgery, emergency, and intensive-care medicine, indicating good potential as a firstline drug for both targeted and empirical therapies.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.
TLDR
Caspofungin appeared to be as effective as and better tolerated than amphotericin B for the treatment of esophageal candidiasis and provides the first demonstration of clinical utility for an echinocandin compound.
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
  • D. Denning, P. Ribaud, H. Lode
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2002
TLDR
Voriconazole is efficacious in treating acute IA and is proven and probable in 68 patients, and good responses were seen in 60% of those with pulmonary or tracheobronchial IA and 26% of allogeneic stem cell transplant recipients.
Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis
TLDR
Results indicate that FK463 may be a potent parenterally administered therapeutic agent for disseminated candidiasis and aspergillosis.
Voriconazole: in the treatment of invasive aspergillosis.
TLDR
Voriconazole was generally well tolerated and showed excellent in vitro activity against Aspergillus spp.
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
TLDR
In patients with invasive aspergillosis,Initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B.
Therapeutic outcome in invasive aspergillosis.
  • D. Denning
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1996
TLDR
In association with pulmonary, sinus, and cerebral aspergillosis in immunocompromised patients, the crude mortality rates were 86%, 66%, and 99%, respectively.
In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi
TLDR
Results from preclinical in vitro evaluations performed thus far indicate that FK463 should be a potent parenteral antifungal agent.
Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Pulmonary Aspergillosis
TLDR
FK463 may be a potent parenterally administered antifungal agent for pulmonary aspergillosis in this animal model, and a significant reduction in viable fungal cells was observed at plasma FK463 levels of 0.55 to 0.80 μg/ml.
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
  • R. Ally, D. Schürmann, A. Romero
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2001
TLDR
Voriconazole (200 mg, b.i.d.) was shown to be at least as effective as fluconazole in the treatment of biopsy-proven esophageal candidiasis in immunocompromised patients.
Resistance of yeasts to azole-derivative antifungals.
  • F. Odds
  • Biology, Medicine
    The Journal of antimicrobial chemotherapy
  • 1993
TLDR
It must be a matter for concern that, by analogy with the known emergence of antibiotic-resistance among bacteria, that the widespread use of a drug inactive against a particular species may lead to an increased incidence of such infections.
...
1
2
3
4
...